S. S. Adam, N. S. Key, and C. S. Greenberg, D-dimer antigen: current concepts and future prospects, Blood, vol.113, issue.13, pp.2878-2887, 2009.

G. D. Lowe, Fibrin D-Dimer and Cardiovascular Risk, Seminars in Vascular Medicine, vol.05, issue.04, pp.387-398, 2005.

W. J. Zi and J. Shuai, Plasma D-Dimer Levels Are Associated with Stroke Subtypes and Infarction Volume in Patients with Acute Ischemic Stroke, PLoS ONE, vol.9, issue.1, p.e86465, 2014.

A. Siegbahn, J. Oldgren, U. Andersson, M. D. Ezekowitz, P. A. Reilly et al., D-dimer and factor VIIa in atrial fibrillation -prognostic values for cardiovascular events and effects of anticoagulation therapy. A RE-LY substudy, Thromb Haemost, vol.115, issue.5, pp.921-951, 2016.

H. Dai, H. Zhou, Y. Sun, Z. Xu, S. Wang et al., D?dimer as a potential clinical marker for predicting metastasis and progression in cancer, Biomedical Reports, vol.9, issue.5, pp.453-457, 2018.

F. Zannad, S. D. Anker, W. M. Byra, J. G. Cleland, M. Fu et al.,

P. Mehra, M. R. Neaton, J. D. Nessel, C. C. Spiro, T. E. Van-veldhuisen et al., Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease, N Engl J Med, 2018.

M. R. Mehra, M. Vaduganathan, M. Fu, J. P. Ferreira, S. D. Anker et al., A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial, European Heart Journal, vol.40, issue.44, pp.3593-3602, 2019.

B. Greenberg, J. D. Neaton, S. D. Anker, W. M. Byra, J. G. Cleland et al., Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm, JAMA Cardiology, vol.4, issue.6, p.515, 2019.

F. Zannad, B. Greenberg, J. G. Cleland, M. Gheorghiade, D. J. Van-veldhuisen et al., Rationale and design of a randomized, double?blind, event?driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF trial, European Journal of Heart Failure, vol.17, issue.7, pp.735-742, 2015.

J. W. Cunningham, J. P. Ferreira, H. Deng, S. D. Anker, W. M. Byra et al., Natriuretic Peptide-Based Inclusion Criteria in a Heart Failure Clinical Trial, JACC: Heart Failure, vol.8, issue.5, pp.359-368, 2020.

J. P. Ferreira, N. Girerd, J. Gregson, I. Latar, A. Sharma et al., Stroke Risk in Patients With Reduced Ejection Fraction After Myocardial Infarction Without Atrial Fibrillation, Journal of the American College of Cardiology, vol.71, issue.7, pp.727-735, 2018.

J. P. Fine and R. J. Gray, A Proportional Hazards Model for the Subdistribution of a Competing Risk, Journal of the American Statistical Association, vol.94, issue.446, pp.496-509, 1999.

I. Kutinsky, S. Blakley, and V. Roche, Normal D-Dimer Levels in Patients With Pulmonary Embolism, Archives of Internal Medicine, vol.159, issue.14, p.1569, 1999.

K. L. Dunn, J. P. Wolf, D. M. Dorfman, P. Fitzpatrick, J. L. Baker et al., Normal d-dimer levels in emergency department patients suspected of acute pulmonary embolism, Journal of the American College of Cardiology, vol.40, issue.8, pp.1475-1478, 2002.

W. Yan, J. Liu, H. Liu, J. Lu, J. Chen et al., Elevated D?dimer levels predict adverse outcomes in hospitalised elderly patients with chronic heart failure, Internal Medicine Journal, vol.49, issue.10, pp.1299-1306, 2019.

G. R. Aispuru, M. M. Clavier, A. J. Cardone, D. O. Gilberto, and A. P. Barousse, Thrombotic biomarkers and left ventricle characteristics as short-term predictors of thrombotic events in patients hospitalized for acute decompensated heart failure, European Journal of Internal Medicine, vol.23, issue.6, pp.545-551, 2012.

C. Christersson, L. Wallentin, U. Andersson, J. H. Alexander, J. Ansell et al., D-dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation - observations from the ARISTOTLE trial, Journal of Thrombosis and Haemostasis, vol.12, issue.9, pp.1401-1412, 2014.

F. Alkhalfan, M. Kerneis, T. Nafee, M. K. Yee, G. Chi et al., D-Dimer Levels and Effect of Rivaroxaban on Those Levels and Outcomes in Patients With Acute Coronary Syndrome (An ATLAS ACS-TIMI 46 Trial Substudy), The American Journal of Cardiology, vol.122, issue.9, pp.1459-1464, 2018.

E. Danese, M. Montagnana, G. Cervellin, and G. Lippi, Hypercoagulability, D-dimer and atrial fibrillation: an overview of biological and clinical evidence, Annals of Medicine, vol.46, issue.6, pp.364-371, 2014.

J. W. Eikelboom, S. J. Connolly, J. Bosch, G. R. Dagenais, R. G. Hart et al., Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease, New England Journal of Medicine, vol.377, issue.14, pp.1319-1330, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01892329

K. R. Branch, J. L. Probstfield, J. W. Eikelboom, J. Bosch, A. P. Maggioni et al., Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease, Circulation, vol.140, issue.7, pp.529-537, 2019.

, Heart Failure with Reduced Ejection Fraction (HFrEF), Encyclopedia of Behavioral Medicine, pp.1047-1047, 2020.

. National-institutes-of-health-(nih), Coronary Artery Disease (CAD), 2007.

. Afib,

H. Hr and . Ratio, Supplemental Information 14: The analysis of Hazard ratio (HR) for TCGA datasets with ccRCC using the eight-CpG-based model in different subgroups stratified by clinical parameters.